Zobrazeno 1 - 10
of 2 273
pro vyhledávání: '"Benralizumab"'
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 1141-1149 (2024)
Yair Humberto González-Tuyub,1 Karla Daniela González-Iñiguez,1 Paula Catalina Lizarazo-Guiza,2 Sergio Ricardo García-García3 1Clinical Immunology and Allergy Service, ISSSTE Hospital Regional General, Ignacio Zaragoza, Ciudad de México, Méxic
Externí odkaz:
https://doaj.org/article/b30297445a9b4004b09fa4d4599aeee0
Autor:
Harada S, Sasano H, Ueda S, Sandhu Y, Abe S, Tanabe Y, Shima K, Kuwano T, Uehara Y, Inoue T, Okumura K, Takahashi K, Harada N
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 1103-1113 (2024)
Sonoko Harada,1,2 Hitoshi Sasano,1 Shoko Ueda,1 Yuuki Sandhu,1 Sumiko Abe,1 Yuki Tanabe,1 Kyoko Shima,3 Tetsuya Kuwano,3 Yuya Uehara,3 Takayoshi Inoue,3 Ko Okumura,2 Kazuhisa Takahashi,1,4 Norihiro Harada1,2,4 1Department of Respiratory Medicine, Jun
Externí odkaz:
https://doaj.org/article/5b3b3853b8654506be64b0f60900aa56
Publikováno v:
Romanian Journal of Internal Medicine, Vol 62, Iss 3, Pp 356-361 (2024)
Eosinophilic Esophagitis is a widely-recognized immune-mediated esophagus disease with distinct clinical and histopathological features, exhibiting an increased global incidence. Therapeutic options encompass either dietary measures or pharmacologica
Externí odkaz:
https://doaj.org/article/f32909de34704dee933a6626ba3721c7
Autor:
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential p
Externí odkaz:
https://doaj.org/article/8a23af9f1a724ed69d43d34d79739f8c
Autor:
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 557-572 (2024)
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich,
Externí odkaz:
https://doaj.org/article/4876db04923144e59915c062279f0c76
Autor:
Christiane E. Whetstone, BSc, Ruth P. Cusack, MB, MPH, Emma Price, MSc, Karen Howie, Catie Stevens, BSc, Dhuha Al-Sajee, MD, PhD, Sue Beaudin, BSc, Jennifer Wattie, Nadia Alsaji, MBChB, Abbey Schlatman, BSc, Vanessa Luk, BHSc, Xiaotian Ju, PhD, Paul O’Byrne, MB, Mark Inman, MD, PhD, Roma Sehmi, PhD, Hermenio Lima, MD, PhD, Gail M. Gauvreau, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 4, Pp 100310- (2024)
Background: Atopic dermatitis (AD) is a skin barrier dysfunction characterized by tissue eosinophilia. Objective: In patients with AD, we evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in skin after intrader
Externí odkaz:
https://doaj.org/article/6a842f379659480d957c7c5a1c8f6866
Autor:
Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F
Publikováno v:
Journal of Asthma and Allergy, Vol Volume 17, Pp 273-290 (2024)
Paolo Cameli,1 Maria Aliani,2 Elena Altieri,3 Pietro Bracciale,4 Luisa Brussino,5 Maria Filomena Caiaffa,6 Giorgio Walter Canonica,7,8 Cristiano Caruso,9 Stefano Centanni,10 Maria D’Amato,11 Fausto De Michele,12 Stefano Del Giacco,13 Fabiano Di Mar
Externí odkaz:
https://doaj.org/article/ac1f80ecdea74103aab26a40cad5bf26
Autor:
Moritz Z. Kayser, Hendrik Suhling, Jan Fuge, Christopher A. Hinze, Nora Drick, Nikolaus Kneidinger, Jürgen Behr, Christian Taube, Tobias Welte, Ina Haasler, Katrin Milger
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. W
Externí odkaz:
https://doaj.org/article/9b65f82e70434ca195edfb5cf288a4e3
Autor:
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko
Publikováno v:
European Clinical Respiratory Journal, Vol 11, Iss 1 (2024)
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre, r
Externí odkaz:
https://doaj.org/article/3a61695cb0444719be9e00172eb6d4dd
Autor:
Maria Basagaña, Carlos Martínez-Rivera, Clara Padró, Ignasi Garcia-Olivé, Mimar Martínez-Colls, Juan Navarro, Laura Pardo, Paula Cruz, Gloria Cardona Peitx, Lídia Carabias, Albert Roger, Jorge Abad, Antoni Rosell
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
AbstractBackground Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered
Externí odkaz:
https://doaj.org/article/4576fc55b49f4d6099db6a806a23639c